Navigation Links
Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer
Date:10/27/2008

gnostic products will be based on the LNA(TM) technology that will enable testing on fixed tissue. The first molecular diagnostic product is scheduled for launch by the end of 2008. A number of new products will follow in the years ahead. Using the LNA(TM) technology is what has allowed Exiqon to establish a position for itself as one of the market's leading providers of research products for gene expression analysis. These research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development various diseases. Exiqon is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biomarkers (Personalized Medicine). Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+). Exiqon is financed until expected breakeven in 2011.

Disclaimer

Forward-looking statements: This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements, which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.


'/>"/>
SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Exiqon: Major Shareholder Announcement
2. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
3. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
4. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
5. Report Regarding the Managements and Closely Related Parties Transactions With Securities in Exiqon A/S
6. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
7. Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc.
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... BELLINGHAM, Washington, USA (PRWEB) November 19, 2014 ... used in our lives was shared with more than ... undergraduate and postgraduate students from the University of Otago ... Outreach Grant . The Otago students, members of the ... Southland New Zealand in early September, giving children from ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 The November ... available as an open access journal featuring the following ... fluorescent proteins to preserve photoresponsiveness in the retina , ... fluorescent in situ hybridization using chromogenic substrates in zebrafish ... DNA, RNA, and protein electrophoresis , Nuclear ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
(Date:11/18/2014)... RPS Diagnostics (RPS®) – a ... announces its third annual partnership of the Centers ... About Antibiotics Week from November 17-23. , Get ... designed to highlight the coordinated efforts of CDC, ... for-profit partners to provide education about the importance ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... Olympus has further,cemented its position as a leader ... exclusive and immediate deal to distribute the products of,Irish ... global,provider of ports for state-of-the-art laparoscopic operative techniques via,a ... now the exclusive,distributor for the full range of products ...
... 11 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... Directors, unexpectedly passed away on Wednesday. Dr. Waltz had been ... At the time of his death, Dr. Waltz served on ... , "The sudden loss of our ...
... Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced ... endpoint in its multi-centre Phase 2 clinical trial ... patients with various sarcomas that have metastasized to ... patients on study with significant, durable, clinically meaningful ...
Cached Biology Technology:Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts 2Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 3Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 4
(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
(Date:11/15/2014)...  While we may still be a few years away ... Trek" to gain instant access to all that ailed his ... and tablets for monitoring and measuring our health are cropping ... seem a tad Orwellian to some, but a new survey ... technological opportunities into their healthcare regime. These are ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... of Velociraptor rewrites evolutionary charts , The recent ... that dromaeosaurs, a group of carnivorous theropods that ... originated much earlier than previously thought. Rather than ... traced back to the Jurassic, possibly as far ...
... a pheromone emitted by older male elephants in musth influences ... surrounding elephants behave, a new study has found. , ... University of Auckland in New Zealand say the release of ... frontalin, depends on whether the male elephant is mature enough ...
... immune system to absorb and digest pathogenic intruders. Some ... multiply within the macrophages. Cell biologists at the University ... recently publication in the journal 'Traffic' (Vol. 6, No. ... pathogens escape the 'stomach' of the macrophages which might ...
Cached Biology News:Newly discovered birdlike dinosaur is oldest raptor ever found in South America 2Newly discovered birdlike dinosaur is oldest raptor ever found in South America 3Newly discovered birdlike dinosaur is oldest raptor ever found in South America 4Male elephants woo females with precise chemistry 2Male elephants woo females with precise chemistry 3Dangerous tricksters: Some bacterie use immune cells to reproduce 2Dangerous tricksters: Some bacterie use immune cells to reproduce 3
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
Biology Products: